Skip to main content
Premium Trial:

Request an Annual Quote

As In Silico Biology Gets Set to Take Off, Market May Impose Barriers

NEW YORK, Nov. 5 - In silico biology is headed for powerful growth in the next five years, but market quirks will likely retard the expansion, a recent report shows.


This market, now worth a mere $27 million, will be worth $205 million by 2007, the according to Front Line Strategic Consulting.


In Front Line's definition, "in silico" biology is research that integrates data from genomics, proteomics and expression experiments to identify drug targets, create pathway and network models, and choose lead compounds.


But there will be major delays before these techniques reach their full potential, Front Line reports. Why the wait? By this analysis, "the poor economic climate, skepticism of the technological value and reduced expenditures on unproven technologies by drug developers" will keep in silico biology in check.


Growth in the near future will be relatively slow as companies struggle against these economic and scientific barriers. New companies will probably enter the market, and the sector as a whole will begin to produce simple pathway models for absorption, metabolism, and elimination of compounds.


Within the next few years, as technologies becomes more robust and the economy warms up, products that analyze cellular pathways and model networks, whole cells, and organ systems will begin growing at a more rapid pace.


By then, in silico biology will also become useful in agriculture, bioprocess engineering, and environmental bioremediation, the report predicts.


Excerpts of the Front Line report can be found on the company's website.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.